Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art
We evaluated the most recent research from 2000 to 2023 in order to deeply investigate the applications of PCa IRE, first exploring its usage with primary intent and then salvage intent. Finally, we discuss the differences with other focal PCa treatments. In the case of primary-intent IRE, the in-fi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/14/2/137 |
| _version_ | 1797297730303819776 |
|---|---|
| author | Eliodoro Faiella Domiziana Santucci Daniele Vertulli Elva Vergantino Federica Vaccarino Gloria Perillo Bruno Beomonte Zobel Rosario Francesco Grasso |
| author_facet | Eliodoro Faiella Domiziana Santucci Daniele Vertulli Elva Vergantino Federica Vaccarino Gloria Perillo Bruno Beomonte Zobel Rosario Francesco Grasso |
| author_sort | Eliodoro Faiella |
| collection | DOAJ |
| description | We evaluated the most recent research from 2000 to 2023 in order to deeply investigate the applications of PCa IRE, first exploring its usage with primary intent and then salvage intent. Finally, we discuss the differences with other focal PCa treatments. In the case of primary-intent IRE, the in-field recurrence is quite low (ranges from 0% to 33%). Urinary continence after the treatment remains high (>86%). Due to several different patients in the studies, the preserved potency varied quite a lot (59–100%). Regarding complications, the highest occurrence rates are for those of Grades I and II (20–77% and 0–29%, respectively). Grade III complications represent less than 7%. Regarding the specific oncological outcomes, both PCa-specific survival and overall survival are 100%. Metastasis-free survival is 99.6%. In a long-term study, the Kaplan–Meier FFS rates reported are 91% at 3 years, 84% at 5 years, and 69% at 8 years. In the single study with salvage-intent IRE, the in-field recurrence was 7%. Urinary continence was still high (93%), but preserved potency was significantly lower than primary-intent IRE patients (23%). In addition, Grade III complications were slightly higher (10.8%). In conclusion, in males with localized low–intermediate-risk prostate cancer, IRE had an excellent safety profile and might have positive results for sexual and urinary function. |
| first_indexed | 2024-03-07T22:25:34Z |
| format | Article |
| id | doaj.art-47f51d98acf14d98ac05f883d5193030 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-07T22:25:34Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-47f51d98acf14d98ac05f883d51930302024-02-23T15:23:39ZengMDPI AGJournal of Personalized Medicine2075-44262024-01-0114213710.3390/jpm14020137Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the ArtEliodoro Faiella0Domiziana Santucci1Daniele Vertulli2Elva Vergantino3Federica Vaccarino4Gloria Perillo5Bruno Beomonte Zobel6Rosario Francesco Grasso7Department of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyDepartment of Radiology, Policlinico “Campus Bio-medico”, Via Alvaro del Portillo, 200-00128 Rome, ItalyWe evaluated the most recent research from 2000 to 2023 in order to deeply investigate the applications of PCa IRE, first exploring its usage with primary intent and then salvage intent. Finally, we discuss the differences with other focal PCa treatments. In the case of primary-intent IRE, the in-field recurrence is quite low (ranges from 0% to 33%). Urinary continence after the treatment remains high (>86%). Due to several different patients in the studies, the preserved potency varied quite a lot (59–100%). Regarding complications, the highest occurrence rates are for those of Grades I and II (20–77% and 0–29%, respectively). Grade III complications represent less than 7%. Regarding the specific oncological outcomes, both PCa-specific survival and overall survival are 100%. Metastasis-free survival is 99.6%. In a long-term study, the Kaplan–Meier FFS rates reported are 91% at 3 years, 84% at 5 years, and 69% at 8 years. In the single study with salvage-intent IRE, the in-field recurrence was 7%. Urinary continence was still high (93%), but preserved potency was significantly lower than primary-intent IRE patients (23%). In addition, Grade III complications were slightly higher (10.8%). In conclusion, in males with localized low–intermediate-risk prostate cancer, IRE had an excellent safety profile and might have positive results for sexual and urinary function.https://www.mdpi.com/2075-4426/14/2/137irreversible electroporationprostate cancercancers treatmentsinterventional radiologyIRE |
| spellingShingle | Eliodoro Faiella Domiziana Santucci Daniele Vertulli Elva Vergantino Federica Vaccarino Gloria Perillo Bruno Beomonte Zobel Rosario Francesco Grasso Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art Journal of Personalized Medicine irreversible electroporation prostate cancer cancers treatments interventional radiology IRE |
| title | Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art |
| title_full | Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art |
| title_fullStr | Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art |
| title_full_unstemmed | Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art |
| title_short | Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art |
| title_sort | irreversible electroporation ire for prostate cancer pca treatment the state of the art |
| topic | irreversible electroporation prostate cancer cancers treatments interventional radiology IRE |
| url | https://www.mdpi.com/2075-4426/14/2/137 |
| work_keys_str_mv | AT eliodorofaiella irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT domizianasantucci irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT danielevertulli irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT elvavergantino irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT federicavaccarino irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT gloriaperillo irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT brunobeomontezobel irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart AT rosariofrancescograsso irreversibleelectroporationireforprostatecancerpcatreatmentthestateoftheart |